Helus Pharma Inc. cash flow statement

In fiscal 2022, Helus Pharma Inc.'s operations generated −$36.1m of cash; it spent $83,781 on capital projects, leaving free cash flow of −$36.2m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Helus Pharma Inc.: cash flow statement, annual
Fiscal year	2021Mar 2021	2022Mar 2022
Cash from operations	−14	−36
Stock-based pay	9	14
Capital spending	0	0
Free cash flow	−15	−36
Free cash flow after stock pay	−23	−51

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Helus Pharma Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Helus Pharma Inc.